Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Keros Therapeutics (KROS) EBIT (2019 - 2025)

Keros Therapeutics filings provide 7 years of EBIT readings, the most recent being -$29.3 million for Q4 2025.

  • On a quarterly basis, EBIT rose 45.04% to -$29.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $67.6 million, a 132.05% increase, with the full-year FY2025 number at $67.6 million, up 132.05% from a year prior.
  • EBIT hit -$29.3 million in Q4 2025 for Keros Therapeutics, down from -$15.4 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $152.0 million in Q1 2025 to a low of -$58.7 million in Q3 2024.
  • Median EBIT over the past 5 years was -$31.3 million (2022), compared with a mean of -$24.2 million.
  • Biggest five-year swings in EBIT: crashed 556.8% in 2022 and later skyrocketed 413.59% in 2025.
  • Keros Therapeutics' EBIT stood at -$4.9 million in 2021, then crashed by 556.8% to -$32.0 million in 2022, then tumbled by 45.35% to -$46.5 million in 2023, then fell by 14.64% to -$53.3 million in 2024, then surged by 45.04% to -$29.3 million in 2025.
  • The last three reported values for EBIT were -$29.3 million (Q4 2025), -$15.4 million (Q3 2025), and -$39.8 million (Q2 2025) per Business Quant data.